Hackura Wellness

08/25/2026

🔥 SLIDING FOR VON: THE LIL DURK TRIAL IS HERE 🔥

One of the biggest trials in hip-hop is now underway.

Lil Durk, whose legal name is Durk Banks, has pleaded not guilty to federal charges arising from an alleged murder-for-hire plot targeting Quando Rondo. Prosecutors allege the 2022 Los Angeles attack was retaliation connected to the death of King Von. Quando Rondo survived, but his cousin Saviay’a “Lul Pab” Robinson was killed. Durk and his defense deny that he organized or funded the attack.

A jury of 12 jurors and four alternates has now been seated, and opening statements were scheduled for August 24. The court has told jurors to prepare for a trial lasting three weeks or longer.

🎤 AND YES, THE MUSIC IS ENTERING THE COURTROOM.

Prosecutors sought to introduce numerous songs or excerpts. The judge substantially narrowed that request, but allowed “Back Again” and “Still Runnin’” into evidence. That could make the fight over whether rap lyrics represent artistic expression or evidence of real-world events one of the most watched parts of this case.

Then there are the alleged cooperating witnesses.

Online discussion has focused heavily on OTF Jam, but remember: claims about what a witness will say are not proof until testimony and evidence are actually presented and tested in court. Reports indicate prosecutors expect roughly 35 witnesses, with about 20 expected to provide substantive testimony.

This is where things get serious.

The government has to prove its case beyond a reasonable doubt. Durk's lawyers get to challenge the government's witnesses, evidence, interpretations of lyrics and alleged connections between Durk and what happened in Los Angeles.

Everybody has theories. Now a jury gets the evidence.

Do you think cooperating OTF members are going to put the government over the top?

Or do you think The Voice walks out of federal court?

👇 DROP YOUR PREDICTION IN THE COMMENTS.

And remember: Lil Durk and his co-defendants are presumed innocent unless proven guilty.

HACKURA WELLNESS
Follow for updates as the trial develops.

08/25/2026

🔫🔫 DITCH THE SWITCH. IT’S NOT WORTH IT.

You may have heard them called switches, buttons, chips, auto sears, or 3D-printed conversion devices.

Whatever name somebody puts on them, understand the facts.

A machinegun conversion device is designed to make a semiautomatic fi***rm fire automatically. Under federal law, ATF considers the conversion device itself a machinegun, even when it isn't installed on a fi***rm. Limited legal exceptions exist, but ordinary unlawful possession can bring serious federal consequences.

3D PRINTED DOES NOT MEAN LEGAL.

ATF has specifically documented 3D-printed conversion devices. Federal authorities have also warned that switches can be made from plastic or metal and manufactured using 3D printers.

And this isn't some outdated problem.

On August 6, 2026, ATF announced an arrest in North Carolina where agents recovered more than 80 suspected machinegun conversion devices. ATF described their proliferation as one of law enforcement's major current concerns and reiterated that they're illegal to make, possess, or sell outside narrow lawful exceptions.

People are actually going to federal prison over these things. In May 2026, a 24-year-old North Carolina man received 30 months in federal prison for possessing a fi***rm equipped with a switch. Another 18-year-old in Michigan received 15 months in June after pleading guilty to possession and transfer of a machinegun in a case involving multiple switches.

One small piece of plastic isn't worth losing your freedom, your future, or somebody else's life.

And don't confuse the recent changes involving suppressors/silencers with machinegun conversion devices. Federal fi***rms laws are complicated, and changes affecting one category do not suddenly make switches legal.

DITCH THE SWITCH.

If you've got young adults in your family who think these things are just another gun accessory, talk to them. A 3D printer doesn't turn an illegal machinegun conversion device into a legal accessory.

HACKURA WELLNESS
Education for the future. Spread awareness before somebody learns the hard way.

08/24/2026

💊 MAT: SHOULD I STAY, OR SHOULD I RUN? 💊
Is medication-assisted treatment recovery, or are we just substituting one opioid for another?

This debate gets heated, so let's deal with the facts.

MAT, now commonly called MOUD when we're talking about opioid use disorder, saves lives. Methadone and buprenorphine are FDA-approved treatments. SAMHSA says these medications improve survival, increase treatment retention and decrease illicit opioid use. They are not considered simply "replacing one addiction with another" when they're being used appropriately to treat opioid use disorder.

METHADONE

Methadone is a long-acting full opioid agonist. Yes, it can cause physical dependence. Stopping it abruptly can cause significant withdrawal.

But that's only half the story.

A stable therapeutic dose can suppress withdrawal and cravings and reduce the effects of other opioids without creating the repeated intoxication-withdrawal cycle associated with uncontrolled short-acting opioid use. SAMHSA says treatment commonly lasts at least 12 months, while some people benefit from much longer maintenance.

SUBOXONE / BUPRENORPHINE

Buprenorphine is a partial opioid agonist. Suboxone combines buprenorphine with naloxone.

It can also produce physical dependence, and stopping it can cause withdrawal. But dependence and addiction aren't automatically the same thing. Someone taking a stable prescribed medication without compulsive drug-seeking behavior isn't necessarily experiencing the same condition they had during active addiction.

Then we have the monthly extended-release buprenorphine injection, SUBLOCADE.

This is where things get interesting for people asking:

"Can I eventually get off everything?"

Because the medication is released slowly from a depot under the skin, buprenorphine levels decline gradually rather than disappearing immediately after someone's final injection. FDA labeling says that after reaching steady state, buprenorphine can remain detectable for 12 months or longer after stopping SUBLOCADE. Patients still need to be monitored for delayed withdrawal.

So how many people actually "walk away" after the shot?

There isn't a good scientific number saying X% of people use SUBLOCADE specifically to taper off buprenorphine and successfully remain medication-free. Be careful when someone gives you one.

But we do have interesting evidence.

The RECOVER study followed 529 people after extended-release buprenorphine treatment. Overall, 47% reported continuous opioid abstinence throughout the entire 18-month follow-up, although 33% reported receiving additional medication treatment after the original trial. Longer exposure to extended-release buprenorphine was associated with better outcomes.

There are also published case reports of people transitioning from daily sublingual buprenorphine to several extended-release injections and then discontinuing buprenorphine with little reported withdrawal. That's promising, but a handful of cases isn't enough to tell us how often that works across the general population.

So...

SHOULD I STAY? SHOULD I RUN?

Maybe that's the wrong question.

If methadone or buprenorphine has stopped someone from overdosing, stabilized their life, restored their family, allowed them to work and kept them away from fentanyl, there isn't a medical prize for getting off medication as quickly as possible.

At the same time, it's completely reasonable for someone who has become stable to eventually discuss a carefully supervised taper or transition with their treatment provider.

Recovery doesn't have to look identical for everybody.

Are you on methadone, Suboxone or SUBLOCADE?

Do you plan on staying on it long term?

Have you successfully gotten completely off MAT/MOUD?

Tell us what actually worked for you. Your experience might help somebody who's struggling with the same decision.

HACKURA WELLNESS
Education. Recovery. Better conversations.

08/24/2026

🍭🍭 HOLD ON, GUYS. HELP MAY BE GETTING EASIER TO REACH. 🍭🍭

For decades, one of the biggest complaints about methadone treatment has been access. People may have to drive long distances, show up frequently at an opioid treatment program, arrange transportation, work around jobs and family, and deal with a system that can make staying in treatment difficult.

That system is changing.

Mobile methadone units are already legal. SAMHSA says mobile medication units can operate as extensions of certified Opioid Treatment Programs and can provide medication, medical services and behavioral-health services to underserved and hard-to-reach communities.

That means the "methadone clinic on wheels" concept isn't science fiction. It's already part of the federal treatment system.

There has also been bipartisan legislation in Congress called the Modernizing Opioid Treatment Access Act (MOTAA). The proposal would go considerably further by allowing certain addiction-medicine physicians to prescribe methadone for opioid use disorder and allowing pharmacies to dispense it, instead of requiring every patient to receive methadone exclusively through the traditional OTP system.

Federal rules have already made other major changes. They allow greater flexibility for take-home methadone, expand which healthcare professionals can participate in treatment, permit certain telehealth evaluations, and encourage mobile medication units to reduce the distance people have to travel for care.

And here's something a lot of people don't realize:

Your insurance may already cover treatment.

Medicare Part B covers methadone and other medications for opioid use disorder when treatment is provided through an eligible Medicare-enrolled OTP. Medicare also covers counseling, therapy, toxicology testing, assessments, peer-recovery support and other services. CMS specifically says covered services can be provided through mobile vans.

For traditional Medicare, CMS says there is no copayment for covered OTP services, although the Part B deductible can apply.

Medicaid is important too. Federal law requires state Medicaid programs to cover qualifying opioid treatment program services, subject to federal and state requirements. Florida received federal approval in February 2026 to continue its mandatory Medicaid benefit for medications for opioid use disorder.

Private insurance coverage varies by company, plan, provider network and state, so always verify your individual benefits before assuming treatment is free.

HOLD ON, GUYS. HELP IS ON THE WAY.

Recovery is hard enough. Getting access to evidence-based treatment shouldn't make it harder.

Would a mobile methadone clinic make treatment easier for you or someone you know?

Would you rather receive treatment through a regular doctor and pharmacy if federal law eventually allows it?

Drop your thoughts below and follow HACKURA WELLNESS for more.

08/24/2026

🍃 **RECOVERY ISN’T FOR THE WEAK. WHAT’S ACTUALLY WORKING FOR YOU?** 🍃

There still aren’t enough good options for people trying to get their lives back.

For some, recovery means **methadone or buprenorphine/Suboxone**. For others, it’s counseling, treatment programs, peer support, exercise, spirituality, lifestyle changes, or a combination of approaches.

And then there are people searching for something different because what they’ve tried simply hasn’t worked for them.

One thing is universal: **withdrawal, cravings, and rebuilding your life can be hard.** Nobody wants to hurt. Nobody wants to wake up sick. And nobody should be ashamed of needing help getting through it.

There isn't one recovery path that works for everybody.

So let’s hear from people who have actually lived it.

**What has worked for YOU?**

How are you handling recovery today? What helped you get through the hardest part? What do you wish someone had told you when you started?

Drop your experience in the comments. Someone reading it may need to hear exactly what you have to say.

**HACKURA WELLNESS**
Education. Awareness. Better conversations about health and recovery.

08/24/2026

🍄🧪 IBOGAINE: ARE WE FINALLY GETTING CLOSER IN AMERICA? 🧪🍄

For years, Americans interested in ibogaine treatment have traveled outside the United States. Now, in 2026, the situation is starting to change.

Ibogaine is a psychoactive compound derived from the African iboga plant. Researchers are investigating it for opioid use disorder, addiction, PTSD, traumatic brain injury, and other difficult-to-treat conditions.

The interest isn't just coming from alternative wellness circles anymore.

The NIH's National Institute on Drug Abuse has awarded more than $2.2 million for a new multi-stage research project examining the safety and preliminary effectiveness of ibogaine for opioid use disorder. The proposed research includes an initial Phase 1 safety study followed by research involving people with OUD who aren't responding adequately to buprenorphine treatment.

And Texas has gone even bigger.

Texas allocated $50 MILLION toward ibogaine research. After proposals from pharmaceutical companies failed to meet the state's requirements, Texas officials announced that the state intends to move forward with its own research program in partnership with Texas medical researchers.

The federal government is moving too.

In April 2026, the FDA announced that it was allowing the first U.S. clinical study of an ibogaine derivative, noribogaine hydrochloride, to proceed under an Investigational New Drug submission. That Phase 1 study is investigating noribogaine as a potential treatment for alcohol use disorder.

In July, HHS and the Department of Veterans Affairs announced a partnership to accelerate research and clinical development of psychedelic treatments, with federal officials specifically discussing ibogaine research and the need for properly controlled trials.

There's even active research at UC Irvine studying brain changes in people with opioid use disorder who independently travel outside the U.S. for legal ibogaine treatment. Researchers are using MRI, spectroscopy, EEG, questionnaires and biological testing before and after treatment. UCI itself does not administer the ibogaine.

So why isn't ibogaine already available everywhere?

Because there is a serious safety issue researchers still have to solve.

Ibogaine can affect the electrical activity of the heart and prolong the QT interval, potentially causing dangerous heart rhythms. That's one major reason current research is focused heavily on dosing, cardiac monitoring and controlled medical administration.

This isn't an FDA-approved miracle cure.

But it's also getting harder to dismiss ibogaine as something nobody serious is studying.

NIH. FDA. HHS. VA. Texas. Major research universities.

The research is moving.

The question is how long it takes before we know whether ibogaine can be made safe and effective enough to become a legitimate treatment option in the United States.

Would you consider ibogaine treatment if it eventually became available through a properly monitored medical program in the U.S.?

Have you already traveled to Mexico, Costa Rica, or somewhere else outside the United States for ibogaine treatment?

If so, what was your experience?

Tell us in the comments. Your experience may help somebody else understand what's actually happening beyond the headlines.

HACKURA WELLNESS
Follow for more research, emerging treatments, recovery information and conversations that deserve more attention.

08/24/2026

🍃💊🍃 IS THERE STILL 7-OH AT YOUR GAS STATION? 🍃💊🍃

It looks like 7-OH products are starting to disappear from some shelves, but the bigger question is: what's coming next?

7-hydroxymitragynine, commonly called 7-OH, is a potent kratom-derived alkaloid that acts at opioid receptors. Concentrated 7-OH products have raised serious concerns about dependence, tolerance, withdrawal, and abuse potential.

Regulators have been increasing scrutiny of concentrated 7-OH products, and some states have already taken action to restrict or prohibit them.

But convenience-store shelves change fast. As one product disappears, new extracts, alkaloids, blends, and products seem to show up.

So I'm curious what people are actually seeing in their own communities:

Is 7-OH still being sold at the gas stations or smoke shops near you?

Has it started disappearing?

And most importantly, are you already seeing something new being marketed to replace it?

Tell me what you're seeing in the comments. Let's keep the conversation focused on facts, recovery, harm reduction, and knowing what's actually being sold.

HACKURA WELLNESS
Education. Awareness. Better questions.

08/24/2026

🧪 SR-17018 🧪
IS THIS THE FUTURE, OR IS IT GETTING TAKEN AWAY TOO SOON?

There is a lot of noise online about SR-17018, especially among people discussing opioid dependence and withdrawal. But let's separate what researchers have actually found from what people are claiming on social media.

SR-17018 is an experimental μ-opioid receptor agonist. It is not an FDA-approved treatment for opioid withdrawal, and there is still extremely limited controlled human evidence.

So why is everybody talking about it?

Researchers studying mice found something unusual. When morphine-dependent mice were switched to SR-17018, it suppressed signs of morphine withdrawal while morphine sensitivity recovered. Researchers also found less tolerance to some effects of SR-17018 compared with morphine and oxycodone.

That's potentially important because medications such as methadone and buprenorphine/Suboxone are established, evidence-based treatments for opioid use disorder, but they can also produce physical dependence and withdrawal when discontinued.

Could a future medication make that transition easier?

Maybe. But we're nowhere near being able to say SR-17018 is that medication.

SR-17018 itself produced physical dependence and withdrawal in the animal research. The withdrawal appeared shorter than morphine withdrawal in that particular mouse experiment, but it was still present.

And there's another major reality check: the original description of SR-17018 as strongly "G-protein biased" has been questioned and refined by subsequent research. Scientists are still working out exactly how this compound interacts with the μ-opioid receptor.

Now things are getting even more interesting.

A 2026 observational report collected self-reported experiences from 55 people with previous opioid use histories. Many reported substantial withdrawal relief and reductions in opioid use while taking SR-17018. But the researchers themselves stressed serious limitations: the information was self-reported, there was no control group, no objective safety monitoring, substantial selection bias, and the results cannot establish that SR-17018 is safe or effective.

That's the part that shouldn't get lost in the hype.

People are discussing SR-17018 in connection with withdrawal from 7-OH, traditional opioids, methadone and Suboxone, but those situations are not interchangeable, and we do not currently have good clinical evidence establishing SR-17018 as a safe treatment for any of them.

No established human dosing.
No established long-term safety profile.
No proven withdrawal protocol.
No FDA-approved indication.

That doesn't make the research meaningless. It means the research needs to catch up with the attention this compound is receiving.

Maybe SR-17018 leads nowhere.

Maybe researchers learn something from it that produces a much better medication.

Or maybe we're watching the early stages of something important.

What's your take on SR-17018? Is this an overlooked direction for opioid-withdrawal research, or are people getting way ahead of the science?

This post is for education and discussion only. It is not medical advice and is not recommending the use of an experimental research chemical.

HACKURA WELLNESS
Question everything. Follow the evidence.

08/24/2026